TABLE 3.
Susceptibility of C. parapsilosis to fluconazole and voriconazole by clinical service
| Clinical service (total no. of isolates)a | Antifungal agent | No. of isolates tested | % of isolates from serviceb | % of isolatesc
|
||
|---|---|---|---|---|---|---|
| S | SDD | R | ||||
| Hematology-oncology (8,432) | Fluconazole | 305 | 3.6 | 94.8 | 2.6 | 2.6 |
| Voriconazole | 301 | 98.7 | 0.7 | 0.7 | ||
| Medical (33,681) | Fluconazole | 2,144 | 6.4 | 93.7 | 2.6 | 3.7 |
| Voriconazole | 2,100 | 96.7 | 1.4 | 2.0 | ||
| Surgical (8,869) | Fluconazole | 561 | 6.3 | 93.9 | 3.0 | 3.0 |
| Voriconazole | 547 | 96.9 | 1.3 | 1.8 | ||
| ICU (18,691) | Fluconazole | 1,119 | 6.0 | 91.3 | 3.6 | 5.1 |
| Voriconazole | 1,083 | 95.3 | 1.4 | 3.3 | ||
| Dermatology (2,519) | Fluconazole | 527 | 20.9 | 93.0 | 4.0 | 3.0 |
| Voriconazole | 502 | 97.2 | 1.2 | 1.6 | ||
| Urology (1,293) | Fluconazole | 61 | 4.7 | 91.8 | 4.9 | 3.3 |
| Voriconazole | 60 | 96.7 | 3.3 | |||
| Outpatient (11,621) | Fluconazole | 811 | 7.0 | 95.2 | 2.8 | 2.0 |
| Voriconazole | 797 | 98.4 | 0.8 | 0.9 | ||
| Other, NOSd (38,649) | Fluconazole | 3,843 | 9.9 | 93.2 | 3.1 | 3.7 |
| Voriconazole | 3,653 | 96.5 | 1.6 | 1.9 | ||
a
That is, the total number of Candida isolates from each service.
b
C. parapsilosis as a percentage of all isolates from that clinical service.
c
S, SDD, and R are as defined in Table 2, footnote a.
d
Other, NOS, other, not otherwise specified.